A Phase II study in adult patients with newly-diagnosed chronic myeloid leukaemia of initial intensified Glivec® therapy, and sequential combination therapy for non-responders, in order to assess response and survival

DOI number 10.58109/6h4q-qf79
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)

Australasian Leukaemia and Lymphoma Group (ALLG)

Timothy Hughes (Institute of Medical and Veterinary Science)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 21 patients with newly diagnosed CML
  • Combination of Pegasys and Glivec treatment.
  • Dataset includes demographic data, diagnostic, treatment data, outcome data

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)

Cancer therapy (excl. chemotherapy and radiation therapy)

ANZCTR Reference ACTRN12607000614493
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au